Alexis Borisy - 05 Jun 2025 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)

Reporting relationship: Director
Issuer ticker: TNGX
Reported as of: 05 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jun 2025, 17:45:23 UTC
Prior SEC filing: 24 Jun 2024
Next SEC filing: 06 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Douglas Barry, as attorney-in-fact

Key filing fact

Alexis Borisy filed Form 4 for Tango Therapeutics, Inc. (TNGX) on 09 Jun 2025.

Key facts

This page summarizes Alexis Borisy's Form 4 filing for Tango Therapeutics, Inc. (TNGX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Jun 2025, 17:45.

Change

Previous filing in this sequence was filed on 24 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001319446 Primary reporting owner

Borisy Alexis

Relationship: Director
Address: C/O TANGO THERAPEUTICS, INC.,, 201 BROOKLINE AVE., SUITE 901, BOSTON
Signature: /s/ Douglas Barry, as attorney-in-fact
Signature date: 09 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TNGX transaction

Common Stock

Award

Transaction value: $0
Shares: +6,250
Change %: +56%
Price: $0.000000
Shares after: 17,500
Date: 05 Jun 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TNGX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +37,500
Change %
Price: $0.000000
Shares after: 37,500
Date: 05 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 37,500
Exercise price: $3.51
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 5, 2026 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

Footnote F2

This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.